StemCell Therapy

Wednesday, 8 July 2020, 2:38 pmPress Release: imsvet

In a twist on new uses of old things, Arthramid Vet isa unique and patented 2.5% cross-linked polyacrylamidehydrogel (PAAG) for intra-articular injection, and the firstPAAG in the world registered for veterinary use. Thisrevolutionary hydrogel contains no active pharmaceuticalingredient and is highly effective, safe and long-lasting.It has been used previously as a dermal filler in cosmeticsurgery but early indications are this new application couldone day even prevent joint damage.

Arthramid Vet isinjected into the joint of animals where it integrates intothe joint capsule of the diseased joint to provide abiocompatible tissue scaffold into which the bodys owntissues grow. This increases the elasticity, strength andstability of the joint resulting in reduced pain andlameness and improved joint function. The first negativeeffects of arthritis seen in a diseased joint.

Thefinal parts of the research conducted in NZ and Australiawere led by two NZ veterinarians and included collaborationwith Otago University and local labs to understand themechanism of action and safety of the product. The product,produced under license in Denmark, is now registered for usein horses in Australia and NZ and signals a move away fromanti inflammatories for managing this debilitatingdisease.

Furthermore, with the welfare of animals, andparticularly race horses, becoming a major focus forindustry groups the potential to reduce the use ofcorticosteroids is another significantbenefit.

Scoop Media

Become a member Find out more

Excerpt from:
NZ Vets Behind Major New Discovery In The Treatment Of Arthritis - Scoop.co.nz

This entry was posted on July 11, 2020 at 10:47 pm and is filed under Arthritis. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |